Nasdaq bounces as oil price softens as US pushes for Iran talks

Iran worries are keeping risk appetites successful check, according to IG's Chris Beauchamp.

“While indices whitethorn person continued to bounce backmost from Monday’s low, the highs of a week agone are inactive to beryllium tested," said Beauchamp.

"This rally doesn’t person the consciousness of April 2025’s tariff intermission bounce, which kicked disconnected an eight-month surge. Instead investors stay cautious, since it is acold from wide immoderate ceasefire talks volition instrumentality place, fto unsocial whether they volition pb to immoderate deal. Iran doesn’t dependable similar it is hopeless for a deal, contempt president Trump’s comments to the contrary.”

Bank of America Global Research said lipid prices are presently successful a “sweet spot” that could support the Federal Reserve somewhat hawkish, depending connected however agelong elevated prices persist.

In a note, analysts astatine Bank of America argued that the cardinal bank’s absorption to an lipid daze tied to geopolitical developments volition beryllium connected the size and duration of the disruption. The Federal Reserve would apt “look through” a impermanent spike successful lipid prices, portion a precise ample daze could punctual a much dovish stance owed to risks to the labour market.

However, the slope said a mean but sustained summation successful lipid prices could person the other effect, reinforcing ostentation pressures and keeping policymakers cautious. In that scenario, the Fed could stay much hawkish, with complaint hikes becoming a anticipation if West Texas Intermediate crude averages astir $80–$100 per tube successful 2026.

The study added that labour marketplace risks would summation non-linearly with the magnitude of the shock, portion ostentation pressures could yet easiness if higher lipid prices importantly weaken demand. Bank of America concluded that existent lipid terms levels autumn wrong the scope wherever ostentation concerns whitethorn outweigh maturation risks, keeping the Fed tilted hawkish for now—though complaint hikes are not its basal case.

Merck & Co Inc (NYSE:MRK, XETRA:6MK) announced connected Wednesday that it volition get US biotech steadfast Terns Pharmaceuticals (NASDAQ:TERN) for $53 per stock successful cash, valuing the institution astatine astir $6.7 billion.

This marks Merck’s 3rd multibillion-dollar acquisition successful the past twelvemonth arsenic the institution looks to fortify its portfolio up of its top-selling crab cause Keytruda losing patent extortion successful 2028.

Terns is processing TERN-701, an oral therapy for chronic myeloid leukemia. Phase 1 proceedings information reported past December showed a large molecular effect complaint of up to 75% astatine 24 weeks, with a tolerable information illustration that supports regular dosing.